New trials and therapies for acute myocardial infarction.
Acute coronary syndromes (ACSs), which include the clinical entities of unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI), account for more than 1.5 million hospital admissions annually in the United States alone. Approximately 1 million of these admissions are classified as UA/NSTEMI and approximately 500,000 are STEMI. Because of the overwhelming number of studies on ACSs over the past several years, this article focuses on new trials and therapies for treating patients diagnosed with STEMI.
Gumina
Richard J
RJ
Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210, USA. Richard.Gumina@osumc.edu
D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007036:Hypothermia, Induced; D009203:Myocardial Infarction / Q000628:therapy*; D010100:Oxygen / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012770:Shock, Cardiogenic / Q000628:therapy; D015607:Stents; D017131:Thrombectomy; D015912:Thrombolytic Therapy
D000925:Anticoagulants; D002317:Cardiovascular Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D010100:Oxygen